Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Patricia Martin-Regueira"'
Autor:
Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Early molecular response (EMR) at 3 months is predictive of improved overall survival (OS) and progression-free survival (PFS) in patients with chronic myeloid leukemia in the chronic phase (CML-CP). Although about one-third of patients treated with
Externí odkaz:
https://doaj.org/article/39e1a5de16144c2285b230f79c731665
Autor:
Neil P. Shah, Valentín García‐Gutiérrez, Antonio Jiménez‐Velasco, Sarah M. Larson, Susanne Saussele, Delphine Rea, François‐Xavier Mahon, Moshe Yair Levy, María Teresa Gómez‐Casares, Michael J. Mauro, Oumar Sy, Patricia Martin‐Regueira, Jeffrey H. Lipton
Publikováno v:
British Journal of Haematology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b65b5007d705c9254abfdc9e17c01e6d
https://doi.org/10.1111/bjh.18883
https://doi.org/10.1111/bjh.18883
Autor:
Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben Mesa, Claire Harrison, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Patricia Martin-Regueira, Christopher Hernandez, Jia Wang, Moshe Talpaz
Publikováno v:
Blood. 140:3935-3937
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7f6ee2c21012cb1bef12aa2cf2250df
https://doi.org/10.1182/blood-2022-156669
https://doi.org/10.1182/blood-2022-156669
Autor:
Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael R. Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio
Publikováno v:
Blood. 140:9647-9649
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed883cc6b53f133882b5f14b1b97ebdc
https://doi.org/10.1182/blood-2022-164444
https://doi.org/10.1182/blood-2022-164444
Autor:
Danny V Jeyaraju, Sheida Hayati, Ann Polonskaia, Maryam Alapa, Manuel Ugidos, Andrew Browne, Alberto Risueño, Patrick Hagner, Vikas Gupta, Moshe Talpaz, Christopher Hernandez, Vincent Chia, Patricia Martin-Regueira, Daniel Lopes de Menezes, Ross La Motte-Mohs, Rajasekhar NVS Suragani, Anita K. Gandhi
Publikováno v:
Blood. 140:3865-3867
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::deb3f2b2d4842bc451d82e70336b717c
https://doi.org/10.1182/blood-2022-166407
https://doi.org/10.1182/blood-2022-166407
Autor:
Patricia Martin-Regueira, Amer M. Zeidan, Hartmut Döhner, Jennifer Lord-Bessen, Eytan M. Stein, Shien Guo, Stéphane de Botton, Pau Montesinos, Paresh Vyas, Andre C. Schuh, Andrew H. Wei, Frederik Lersch, Ling Shi, Courtney D. DiNardo, Jing Gong, Clara Chen
BACKGROUND: IDH2 mutations occur in 8-19% of patients (pts) with AML. ENA is an oral, selective IDH2 inhibitor and AZA is a hypomethylating agent. In a phase 1b/2 trial, combination therapy with ENA + SC AZA significantly improved overall response ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1829e0ecc3394389229a1ddea6b4866b
https://doi.org/10.1182/blood-2021-147601
https://doi.org/10.1182/blood-2021-147601
Autor:
Stéphane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Jörg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, Maria Belen Vidriales, Vadim Doronin, Hartmut Döhner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Courtney D. DiNardo
Publikováno v:
Scientia
Enasidenib; Conventional care Enasidenib; Atenció convencional Enasidenib; Atención convencional This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3715a5d50e378580e2588f9f261b90de
https://ora.ox.ac.uk/objects/uuid:f5d7e243-e3f5-4a9c-b91e-69a2fc98cc60
https://ora.ox.ac.uk/objects/uuid:f5d7e243-e3f5-4a9c-b91e-69a2fc98cc60
Autor:
Rene Swanink, Lambert Busque, Patricia Martin Regueira, Satu Mustjoki, Rebecca B. Klisovic, Dominik Wolf, Joaquin Martinez-Lopez, Juan Carlos Hernández-Boluda, Kimmo Porkka, Jeffrey H. Lipton
Publikováno v:
Leukemia & Lymphoma. 62:2040-2043
Although treatment with tyrosine kinase inhibitors (TKIs) has dramatically improved outcomes for the majority of patients with chronic myeloid leukemia (CML), approximately 20–30% will require a ch...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be46f77b4bbaf846a60e482a25fb7ab4
https://doi.org/10.1080/10428194.2021.1889536
https://doi.org/10.1080/10428194.2021.1889536
Autor:
Courtney D. DiNardo, Stéphane de Botton, Alberto Risueño, Andre C. Schuh, Bob Löwenberg, Hee-Je Kim, Paresh Vyas, Andrew H. Wei, Eytan M. Stein, Hartmut Döhner, Amir T. Fathi, Patricia Martin-Regueira, Lilia Taningco, Iryna Bluemmert, Xin Yu, Wendy L. See, Maroof Hasan
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S249-S250
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::378f36a9d79a8130bc59e00dcb3445a6
https://doi.org/10.1016/s2152-2650(22)01293-9
https://doi.org/10.1016/s2152-2650(22)01293-9
Autor:
Jerald P. Radich, Patricia Martin-Regueira, Huanling Zhu, Dong-Wook Kim, Xiaoli Liu, Qian Jiang, Renuka Gurnani, Andreas Hochhaus, Jianxiang Wang, Michael R. Savona, Giuseppe Saglio, Jorge E. Cortes, Oumar Sy, Jianyu Weng
Publikováno v:
Leukemia
Early molecular response is associated with improved probability of deep molecular response and superior survival in patients with CML-CP. However, ~1 in 3 patients on first-line imatinib do not achieve this threshold. The phase 2b DASCERN trial (NCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e5c674c294992cd9123adf94b9784d9
https://doi.org/10.1038/s41375-020-0805-1
https://doi.org/10.1038/s41375-020-0805-1